SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31: 51925
  • 2
    Young A, Cox N, Davis P, Dixie J, Emery P, James D, et al. Early rheumatoid arthritis: clinical patterns and outcome during the first 3 years in 207 patients. Br J Rheumatol 1993; 32 Suppl: 97.
  • 3
    Paget SA. Arthritis therapies: where are we now? J Musculoskel Med 2000; 17 Suppl: 715.
  • 4
    Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981–1996. J Rheumatol 1998; 25: 4081.
  • 5
    Suarez-Almazor ME, Soskolne CL, Saunders LD, Russell AS. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta: patterns of prescription and long-term effectiveness. J Rheumatol 1995; 22: 83643.
  • 6
    Cush JJ, Kavanaugh AF, Lipsky PE, Arthritis Care Algorithm Steering Committee. 1995 national survey of US rheumatologists: beliefs and practices regarding therapy, referrals, managed care, guidelines and algorithms [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S16.
  • 7
    Wolfe F, Albert DA, Pincus T. A survey of United States rheumatologists concerning effectiveness of disease-modifying antirheumatic drugs and prednisone in the treatment of rheumatoid arthritis. Arthritis Care Res 1998; 11: 37581.
  • 8
    Finck B, Martin R, Fleischmann R, Morelan L, Schiff M, Bathon J. A phase III trial of etanercept vs methotrexate (MTX) in early rheumatoid arthritis [abstract]. Arthritis Rheum 1999; 42 Suppl 9: S11.
  • 9
    Genovese M, Martin R, Fleischmann R, Keystone E, Bathon J, Spencer-Green G, et al. Enbrel (etanercept) vs methotrexate (MTX) in early rheumatoid arthritis: two-year followup [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S26.
  • 10
    Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 158693.
  • 11
    Lipsky P, van der Heijde D, St. Clair W, Smolen J, Furst D, Kalden J, et al. 102-wk clinical and radiologic results from the ATTRACT trial: a 2-year, randomized, controlled, phase 3 trial of infliximab in patients with active RA despite MTX [abstract]. Arthritis Rheum 2000; 43 Suppl 9: S26.
  • 12
    Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594602.
  • 13
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Celecoxib Long-term Arthritis Safety Study, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000; 284: 124755.
  • 14
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, VIGOR Study Group. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 15208.
  • 15
    2001 Drug topics red book. New Jersey: Medical Economics; 2001. p. 304, 493.
  • 16
    Proudman SM, Conaghan PG, Richardson C, Griffiths B, Green MJ, McGonagle D, et al. Treatment of poor-prognosis early rheumatoid arthritis: a randomized study of treatment with methotrexate, cyclosporin A, and intraarticular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 180910.
  • 17
    Berard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. J Rheumatol 2000; 27: 16485.
  • 18
    Prashker MJ, Meenan RF. The total costs of drug therapy for rheumatoid arthritis: a model based on costs of drug, monitoring, and toxicity. Arthritis Rheum 1995; 38: 31825.
  • 19
    Melton LJ 3rd, Dyck PJ, Karnes JL, O'Brien PC, Service FJ. Non-response bias in studies of diabetic complications: the Rochester Diabetic Neuropathy Study. J Clin Epidemiol 1993; 46: 3418.